Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO): A Novel Retinal Metabolic Biomarker for Multiple Sclerosis

Authors

Daniel Markowitz, Thomas Jefferson UniversityFollow
Kylee Shivok, Thomas Jefferson UniversityFollow
Elizabeth Affel, MS, Thomas Jefferson UniversityFollow
Jose S. Pulido, MD, MS, MBA, MPH, Thomas Jefferson UniversityFollow
Thomas P. Leist, MD, PhD, Thomas Jefferson UniversityFollow
Gyorgy Hajnoczky, MD, PhD, Thomas Jefferson UniversityFollow
Mahdi Alizadeh, PhD, Thomas Jefferson UniversityFollow
Robert Sergott, MD, Thomas Jefferson UniversityFollow

Document Type

Poster

Publication Date

2-28-2025

Comments

Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025.

Abstract

Introduction

- Fluorescence lifetime imaging ophthalmoscopy (FLIO, Heidelberg Engineering, Figures 1 and 2), a novel in vivo retinal imaging biomarker, generates fluorescence decay lifetimes in 2 spectral channels corresponding to the following metabolic processes:

- Short Spectral Channel (SSC): 498 – 560 nm

• Corresponds to macular pigment, flavin adenine dinucleotide (FAD) and oxidative phosphorylation.

- Long Spectral Channel (LSC): 560 – 720nm

• Corresponds to predominantly lipofuscin and lysosomal function

- Based upon animal experimental models and clinical data, mitochondrial dysfunction has a role in the pathophysiology of both inflammatory and degenerative components of Multiple Sclerosis

Recommended Citation

Markowitz, Daniel; Shivok, Kylee; Affel, MS, Elizabeth; Pulido, MD, MS, MBA, MPH, Jose S.; Leist, MD, PhD, Thomas P.; Hajnoczky, MD, PhD, Gyorgy; Alizadeh, PhD, Mahdi; and Sergott, MD, Robert, "Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO): A Novel Retinal Metabolic Biomarker for Multiple Sclerosis" (2025). Farber Institute for Neuroscience Staff Papers and Presentations. Paper 8.
https://jdc.jefferson.edu/farberneurospapers/8

Language

English